ArticleInfection and drug resistance2025
Influence of Type 2 Diabetes Mellitus on the Clinical Outcomes in Hospitalized Patients with Active Pulmonary Tuberculosis: A Retrospective, Single-Center, Real-World Study in China.
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Treatment outcomes and clinical characteristics in diabetic versus non-diabetic sinonasal tuberculosis.Bioinformation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To explore the influence of type 2 diabetes mellitus (T2DM) on the clinical outcomes of pulmonary tuberculosis (TB) and the factors that may affect outcomes. In addition, the treatment regimens of active pulmonary TB patients with or without T2DM were described. Methods: This is a retrospective, single-center, real-world study conducted in the Fifth People's Hospital of Suzhou (China), an urban hospital. This study divided 340 inpatients with active TB who received standard anti-tuberculosis treatment into the T2DM and control groups, with 61 patients in the T2DM group and 279 patients in the control group. The outcomes were the time to negative Results: The percentage of patients who received the isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE) regimen was numerically lower in the T2DM vs control group (73.8% vs 79.6%), while the use of the isoniazid, rifapentine, ethambutol, and levofloxacin (HRftELfx) regimen was numerically higher (14.8% vs 9.7%). The median time to negative sputum conversion was longer in the T2DM group (median, 60.00 vs 52.00 days, P<0.001). The rates of negative sputum conversion at 2 months were 85.2% vs 92.8% in the T2DM and control groups (P=0.055). The multivariable Cox regression analysis showed that the male sex (adjusted HR=0.759, 95% CI: 0.585-0.984, P=0.037) and T2DM (adjusted HR=0.721, 95% CI: 0.528-0.986, P=0.040) were independently associated with the time to negative sputum Conclusion: Patients with TB and T2DM had a longer time to negative sputum
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.